KEAP1 and lung carcinoma: In addition, the activity of NRF2 positively reflects erastin resistance in isogenic lung cancer cell models, regardless of Kelch-like ECH-associated protein 1(KEAP1) mutation (28), a molecule that represses NRF2 via its ubiquitin proteasomal degradation in normal conditions (29).